Doxifluridine Tablets

Pharmacological action: Deoxyfluridine tablets are a fluorouracil derivative, which is converted into fluorouracil (5-Fu) by highly active pyrimidine nucleoside phosphorylase in tumor tissue, exerting its selective anti-tumor effect. Experiments show that the therapeutic index of deoxyfluridine is higher than that of 5-Fu. Toxicological study: The acute toxicity test measured that the D50 values of mice for oral administration and intraperitoneal injection were 2.45 g/kg and 4.20 g/kg, respectively, and the 95% confidence limits were 2.175-2.770 g/kg and 4.014-4.401 g/kg, respectively. Subacute oral administration of this product for 13 weeks was 15.35.85.200 mg/kg/day. A decrease in thymus weight occurred above 85 mg/kg, and a suppression of weight gain, obstructive urinary protein, and a reduction in thymus and testis at 200 mg/kg. Chronic toxicity: Oral administration of this product for 26 weeks at 15, 35, 85, 200 mg/kg/day. Over 85 mg/kg causes chest hair loss and obstructive urine protein. Over 200 mg/kg causes weight gain inhibition, bleeding, decreased nucleocyte count, swelling, and thymus shrinkage. Reproductive toxicity: Oral administration of this product at 25.50 and 100 mg/kg/day before pregnancy and at the beginning of pregnancy. Over 50 mg/kg causes bone variation in the fetus. Over 50 mg/kg causes bone variation in the fetus during organ formation, delayed ossification, abnormal appearance, etc. Over 100 mg/kg causes low survival rate. Over 25.50 and 100 mg/kg/day causes abnormalities in newborns during lactation. Other reports: When dogs are given large amounts of deoxyfluridine (over 10 mg/kg) orally, abnormal lesions occur in the brain parenchyma and small hemorrhages occur in the cerebrospinal cord.

Chemical name: 5'-deoxy-5-fluorouridine Chemical structure: Molecular formula: C9H11FN2O5 Molecular weight: 246.20

This product is a film-coated tablet, which appears white or off-white after removing the film.

This product is used for gastric cancer, colon cancer, rectal cancer, breast cancer, cervical cancer, and bladder cancer.

Oral administration, total daily dose 0.8-1.2 g (4-6 tablets), divided into 3-4 times. The dose may be increased or decreased appropriately according to age and symptoms, or as directed by a doctor. When used with other anti-tumor drugs, please follow the doctor's advice.

At the commonly used dose, this product is well tolerated, but sometimes the following adverse reactions may occur: 1. Digestive system: diarrhea, nausea, vomiting, loss of appetite, occasionally dry mouth, cheilitis, abdominal pain, abdominal distension, constipation, gastritis, paralytic ileus, rare gastrointestinal bleeding, gastric ulcer, glossitis, etc.; 2. Blood: leukopenia, decreased hemoglobin, occasionally thrombocytopenia, anemia and other symptoms may occur. 3. Liver: Occasionally, OT, PT, AI-P, BI rise and other symptoms are increased. 4. Kidney: Occasionally, BUN rise, hematuria, protein, frequent urination and other symptoms are seen. 5. Mental and nervous system: Occasionally, there are symptoms such as fatigue, dizziness, headache, drowsiness, tinnitus, unsteady steps, disorientation, perversion of smell, slurred speech, decreased taste, etc. There are also reports of similar compounds (such as Kamov) causing leukoencephalopathy. 6. Skin: Occasionally, there are pigmentation, itching, hair loss, rare finger and toe nail abnormalities and dermatitis. 7. Circulatory system: Rare symptoms include chest tightness, palpitations, abnormal electrocardiogram (ST segment elevation), etc. 8. Allergies: Occasionally, there may be rash, eczema, urticaria, and rare photosensitivity. 9. Others: Sometimes, there may be fever, throat discomfort, eye fatigue, etc.

1. Patients with a history of severe disease should not take this drug; patients who are taking SORIVUDINE should not take this drug; 2. It is best not to administer the drug to pregnant women or women who may become pregnant. When breastfeeding women use this drug, they should stop breastfeeding; 3. Children should use this drug with caution and pay special attention to the appearance of side effects. When using this drug in children, the effect on the gonads must be considered.

Precautions for children: Use with caution in children. Precautions for pregnancy and lactation: 1. According to animal experiments (mice), it is reported that it has teratogenic effects. It is best not to use the drug for lactating women. 2. According to animal experiments (mice), it is reported that the drug will enter the breast milk. Therefore, if the drug is taken during lactation, breastfeeding should be stopped.

When used in combination with other anti-tumor drugs, adverse reactions such as bone marrow suppression may be aggravated. When the antiviral drug Sorivudine is used in combination with this product or fluorouracil, it can hinder the metabolism of the latter, leading to increased blood concentrations, significant bone marrow suppression, and severe blood toxicity that can lead to death, so it is strictly prohibited to use it in combination.

Keep in a dark, cool place (no more than 20℃) and seal tightly

0.2g

Tentative 24 months

Fuan Pharmaceutical Group Ningbo Team Pharmaceutical Co., Ltd.

• Founded in:

  1992-08-12

• Address:

  No. 366, Anping Road, Zhaobaoshan Street, Zhenhai District, Ningbo City, Zhejiang Province

• Tax NO.:

  91330211144072003N

• Registered Funds:

  415 million yuan

• Website:

  Log in to view

• Email:

  Log in to view